PAIN
Volume 146, Issue 1 , Pages 26-33 , November 2009

Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia

Received 6 February 2009 ,Revised 28 April 2009 ,Accepted 27 May 2009.

References 

  1. Ablin J, Neumann L, Buskila D. Pathogenesis of fibromyalgia – a review. Joint Bone Spine. 2008;75:273–279
  2. Arendt-Nielsen L, Graven-Nielsen T, Svensson P, Jensen TS. Temporal summation in muscles and referred pain areas: an experimental human study. Muscle Nerve. 1997;20:1311–1313
  3. Arnold LM. Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Res Ther. 2006;8:212
  4. Barasi S, Duggal KN. The effect of local and systemic application of dopaminergic agents on tail flick latency in the rat. Eur J Pharmacol. 1985;117:287–294
  5. Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci. 1984;7:309–338
  6. Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc. 1999;74:385–398
  7. Bradley LA. Pathophysiologic mechanisms of fibromyalgia and its related disorders. J Clin Psychiatry. 2008;69:6–13
  8. Burgmer M, Pogatzki-Zahn E, Gaubitz M, Wessoleck E, Heuft G, Pfleiderer B. Altered brain activity during pain processing in fibromyalgia. Neuroimage. 2009;44:502–508
  9. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53:55–63
  10. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol. 2003;17:685–701
  11. Colpaert FC. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology. 1987;26:1431–1440
  12. Cook DB, Lange G, Ciccone DS, Liu WC, Steffener J, Natelson BH. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol. 2004;31:364–378
  13. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–1273
  14. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther. 2000;295:1086–1093
  15. Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237–251
  16. Field MJ, Bramwell S, Hughes J, Singh L. Detection of static and dynamic components of mechanical allodynia in rat models of neuropathic pain: are they signalled by distinct primary sensory neurones?. Pain. 1999;83:303–311
  17. Finch L, Leach GD. The contribution of the sympathetic nervous system to the development and maintenance of experimental hypertension in the rat. Br J Pharmacol. 1970;39:317–324
  18. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986;29:1371–1377
  19. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46:1333–1343
  20. Heslop KE, Curzon G. Depletion and repletion of cortical tissue and dialysate 5-HT after reserpine. Neuropharmacology. 1994;33:567–573
  21. Heymann RE, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clin Exp Rheumatol. 2001;19:697–702
  22. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 2005;52:2495–2505
  23. Huang QJ, Jiang H, Hao XL, Minor TR. Brain IL-1 beta was involved in reserpine-induced behavioral depression in rats. Acta Pharmacol Sin. 2004;25:293–296
  24. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM. Efficacy of duloxetine, a potent and balanced serotonin–norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther. 2004;311:576–584
  25. Kehl LJ, Trempe TM, Hargreaves KM. A new animal model for assessing mechanisms and management of muscle hyperalgesia. Pain. 2000;85:333–343
  26. Kulkarni SK, Mehta AK. Purine nucleoside-mediated immobility in mice: reversal by antidepressants. Psychopharmacology (Berlin). 1985;85:460–463
  27. Kulkarni SK, Robert RK. Reversal by serotonergic agents of reserpine-induced hyperalgesia in rats. Eur J Pharmacol. 1982;83:325–328
  28. Legangneux E, Mora JJ, Spreux-Varoquaux O, Thorin I, Herrou M, Alvado G, et al. Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology (Oxford). 2001;40:290–296
  29. Leith NJ, Barrett RJ. Effects of chronic amphetamine or reserpine on self-stimulation responding: animal model of depression?. Psychopharmacology (Berlin). 1980;72:9–15
  30. Maj J, Rogóz Z, Skuza G, Kołodziejczyk K. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol. 1997;324:31–37
  31. Malt EA, Olafsson S, Aakvaag A, Lund A, Ursin H. Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord. 2003;75:77–82
  32. Marcus DA. Current trends in fibromyalgia research. Expert Opin Pharmacother. 2003;4:1687–1695
  33. Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36:398–409
  34. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP, Martin SA, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502–514
  35. Mense S. Neurobiological concepts of fibromyalgia – the possible role of descending spinal tracts. Scand J Rheumatol Suppl. 2000;113:24–29
  36. Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol. 1992;215:161–170
  37. Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66:355–474
  38. Minor TR, Huang Q, Foley EA. Cytokine-purine interactions in behavioral depression in rats. Integr Physiol Behav Sci. 2003;38:189–202
  39. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977;266:730–732
  40. Price DD, Staud R, Robinson ME, Mauderli AP, Cannon R, Vierck CJ. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain. 2002;99:49–59
  41. Rao SG, Bennett RM. Pharmacological therapies in fibromyalgia. Best Pract Res Clin Rheumatol. 2003;17:611–627
  42. Ren K, Dubner R. Descending modulation in persistent pain: an update. Pain. 2002;100:1–6
  43. Rooks DS. Fibromyalgia treatment update. Curr Opin Rheumatol. 2007;19:111–117
  44. Russell IJ, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol. 2000;6:250–257
  45. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136:432–444
  46. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35:550–556
  47. Schäfers M, Sorkin LS, Sommer C. Intramuscular injection of tumor necrosis factor-alpha induces muscle hyperalgesia in rats. Pain. 2003;104:579–588
  48. Schuldiner S, Shirvan A, Linial M. Vesicular neurotransmitter transporters: from bacteria to humans. Physiol Rev. 1995;75:369–392
  49. Sluka KA, Kalra A, Moore SA. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve. 2001;24:37–46
  50. Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep. 2002;4:299–305
  51. Staud R, Rodriguez ME. Mechanisms of disease: pain in fibromyalgia syndrome. Nat Clin Pract Rheumatol. 2006;2:90–98
  52. Suarez-Roca H, Quintero L, Arcaya JL, Maixner W, Rao SG. Stress-induced muscle and cutaneous hyperalgesia: differential effect of milnacipran. Physiol Behav. 2006;88:82–87
  53. Tamae A, Nakatsuka T, Koga K, Kato G, Furue H, Katafuchi T, et al. Direct inhibition of substantia gelatinosa neurones in the rat spinal cord by activation of dopamine D2-like receptors. J Physiol. 2005;568:243–253
  54. Vetulani J, Antkiewicz-Michaluk L, Rokosz-Pelc A, Michaluk J. Effects of chronically administered antidepressants and electroconvulsive treatment on cerebral neurotransmitter receptors in rodents with ‘model depression’. Ciba Found Symp. 1986;123:234–245
  55. Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol. 1997;14:2–31
  56. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19–28
  57. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160–172
  58. Wood PB. Stress and dopamine: implications for the pathophysiology of chronic widespread pain. Med Hypotheses. 2004;62:420–424
  59. Wood PB. Role of central dopamine in pain and analgesia. Expert Rev Neurother. 2008;8:781–797
  60. Wood PB, Holman AJ, Jones KD. Novel pharmacotherapy for fibromyalgia. Expert Opin Investig Drugs. 2007;16:829–841
  61. Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum. 2007;36:339–356
  62. Yunus MB, Masi AT, Aldag JC. Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. J Rheumatol. 1989;16:527–532
  63. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 1983;16:109–110

PII: S0304-3959(09)00316-9

doi: 10.1016/j.pain.2009.05.024

PAIN
Volume 146, Issue 1 , Pages 26-33 , November 2009

Article Tools

* Image Usage & Resolution